Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Andrew Carr

ChM DSc FRCS FMedSci


Head of Department

  • Nuffield Professor of Orthopaedics
  • Director of the Botnar Research Centre

 

Andrew Carr is the Nuffield Professor of Orthopaedic Surgery at the University of Oxford where he is Head of Department and Director of the Botnar Research Centre. 

 

He is past President of the British Shoulder and Elbow Surgery Society and remains clinically active. His research has focussed on the development and evaluation of surgical implants and technologies. Whilst working with John Goodfellow he defined the use of the Oxford Knee as a partial knee replacement which has been implanted in over 1.5 million people worldwide. He has pioneered the importance of patients’ views in assessing the outcome of surgery and the Oxford Scores, which he coinvented, are now used globally to assess patient outcomes and direct health policy. Both the Oxford Scores and the Oxford Knee were submitted for their impact in the REF 2014.  He has improved the National infrastructure for clinical trials of surgery in the UK and co-founded the Royal College of Surgeons of England Trial Unit in Oxford in 2012.  He has been chief investigator of multicentre randomised controlled trials of surgery that have improved the care of patients undergoing surgery including defining the indications for, and ethics of, placebo surgery controls in surgical trials. He is author of over 450 papers and review articles, including more than 20 in the Lancet and BMJ, which have been cited over 31,000 times. He has raised over £30 million to construct the Botnar Research Centre complex which houses over 250 multidisciplinary researchers. He was Director of the NIHR Biomedical Research Unit in Oxford from 2008-2017 focussing on translational research. He was instrumental in the relocation of the Kennedy Institute for Rheumatology to Oxford and NDORMS in 2013 with an investment of over £60 million from the Kennedy Trust. He has held leadership, trustee and advisory roles with charities, Universities and research councils in the UK and internationally. He is an NIHR senior investigator and was elected a fellow of the Academy of Medical Sciences in 2009. 

 

Key publications

Recent publications

More publications

Biopatch